ProQR Therapeutics (NASDAQ:PRQR) Given New $2.00 Price Target at Citigroup

ProQR Therapeutics (NASDAQ:PRQR) had its target price increased by Citigroup from $1.80 to $2.00 in a research report sent to investors on Thursday, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

A number of other brokerages have also recently issued reports on PRQR. StockNews.com cut ProQR Therapeutics from a buy rating to a hold rating in a report on Tuesday, March 19th. HC Wainwright reiterated a buy rating and set a $5.00 price target on shares of ProQR Therapeutics in a report on Thursday, March 14th. Finally, Chardan Capital boosted their target price on ProQR Therapeutics from $2.00 to $2.50 and gave the company a buy rating in a research note on Thursday, March 14th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, ProQR Therapeutics currently has an average rating of Moderate Buy and an average price target of $3.60.

ProQR Therapeutics Stock Performance

PRQR opened at $1.86 on Thursday. ProQR Therapeutics has a one year low of $1.11 and a one year high of $3.29. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.54 and a quick ratio of 3.54. The stock’s fifty day moving average is $2.14 and its 200-day moving average is $1.87.

ProQR Therapeutics (NASDAQ:PRQR) last posted its quarterly earnings data on Wednesday, March 13th. The biopharmaceutical company reported ($0.08) EPS for the quarter, hitting analysts’ consensus estimates of ($0.08). ProQR Therapeutics had a negative return on equity of 56.71% and a negative net margin of 431.65%. The company had revenue of $3.54 million for the quarter, compared to the consensus estimate of $27.88 million. On average, equities research analysts forecast that ProQR Therapeutics will post -0.37 EPS for the current year.

Institutional Trading of ProQR Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Monaco Asset Management SAM lifted its position in shares of ProQR Therapeutics by 58.9% in the third quarter. Monaco Asset Management SAM now owns 377,517 shares of the biopharmaceutical company’s stock worth $491,000 after buying an additional 140,000 shares during the last quarter. Millennium Management LLC acquired a new position in shares of ProQR Therapeutics during the 4th quarter worth about $699,000. Mariner LLC acquired a new position in shares of ProQR Therapeutics during the 4th quarter worth about $68,000. Boothbay Fund Management LLC acquired a new position in shares of ProQR Therapeutics during the 4th quarter worth about $334,000. Finally, Marshall Wace LLP lifted its position in shares of ProQR Therapeutics by 472.8% during the 4th quarter. Marshall Wace LLP now owns 420,615 shares of the biopharmaceutical company’s stock worth $1,556,000 after purchasing an additional 347,185 shares during the last quarter. Institutional investors and hedge funds own 32.65% of the company’s stock.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).